BIOCEPT, INC. (NASDAQ:BIOC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02

As discussed below in Item 5.07, on May 2, 2017, Biocept, Inc.
(the Company) held its 2017 Annual Meeting of Stockholders (the
Annual Meeting) at which the Companys stockholders approved the
Companys Amended and Restated 2013 Equity Incentive Plan, as
amended (the 2013 Plan), to, among other things, increase the
number of shares of the Companys common stock available for
issuance under the 2013 Plan from 1,022,955 to 3,522,955. A
summary of the material terms of the 2013 Plan is set forth in
the Companys definitive proxy statement for the Annual Meeting
filed with the Securities and Exchange Commission on March 30,
2017. That summary is qualified in its entirety by reference to
the text of the 2013 Plan, which is filed as Exhibit 99.1 hereto
and incorporated herein by reference.

On May 2, 2017, the Company held the Annual Meeting. As of March
22, 2017, the record date for the Annual Meeting, 22,240,247
shares of common stock were outstanding and entitled to vote at
the Annual Meeting. At the Annual Meeting, 16,137,288 shares of
common stock were present in person or represented by proxy for
the four proposals summarized below.

Proposal 1:Election of Directors

The Companys stockholders elected the two persons listed below to
serve until the Companys 2020 Annual Meeting of Stockholders. The
final voting results are as follows:

Proposal 2:Ratification of the Selection of Independent
Registered Public Accounting Firm

The Companys stockholders ratified the selection by the Audit
Committee of Mayer Hoffman McCann P.C. as the Companys
independent registered public accounting firm for the fiscal year
ending December 31, 2017. The final voting results are as
follows:

Proposal 3:Approval of Amended and Restated 2013 Equity Incentive
Plan, as amended

The Companys stockholders approved the Companys Amended and
Restated 2013 Equity Incentive Plan, as amended. The final voting
results are as follows:

Proposal 4:Authorize to adjourn the Annual Meeting

The Companys stockholders approved the authorization to adjourn
the Annual Meeting, if necessary, to solicit additional proxies
if there were not sufficient votes in favor of Proposal 3. The
final voting results are as follows:

(d) Exhibits

About BIOCEPT, INC. (NASDAQ:BIOC)

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

BIOCEPT, INC. (NASDAQ:BIOC) Recent Trading Information

BIOCEPT, INC. (NASDAQ:BIOC) closed its last trading session down -0.02 at 1.63 with 727,816 shares trading hands.